EyePoint Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
EyePoint Pharmaceuticals Il CEO è Jay Duker, nominato in Jan2023, e ha un mandato di 1.83 anni. la retribuzione annua totale è $ 2.92M, composta da 21.1% di stipendio e 78.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.091% delle azioni della società, per un valore di $ 751.01K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 3.3 anni.
Informazioni chiave
Jay Duker
Amministratore delegato
US$2.9m
Compenso totale
| Percentuale dello stipendio del CEO | 21.1% |
| Mandato del CEO | 1.8yrs |
| Proprietà del CEO | 0.09% |
| Durata media del management | 1.8yrs |
| Durata media del Consiglio di amministrazione | 3.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
Oct 29
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$79m |
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$75m |
| Mar 31 2019 | n/a | n/a | -US$98m |
| Dec 31 2018 | US$27k | n/a | -US$86m |
Compensazione vs Mercato: La retribuzione totale di Jay ($USD 2.92M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 3.23M ).
Compensazione vs guadagni: La retribuzione di Jay è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Jay Duker (65 yo)
1.8yrs
Mandato
US$2,915,146
Compensazione
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 1.8yrs | US$2.92m | 0.091% $ 751.0k | |
| Executive VP & CFO | 5yrs | US$1.78m | 0.072% $ 589.1k | |
| Interim Head of R&D and Director | less than a year | US$161.67k | 0.017% $ 141.5k | |
| Senior Vice President of Manufacturing & Operations | 1.3yrs | Nessun dato | Nessun dato | |
| Chief Legal Officer & Company Secretary | 6yrs | Nessun dato | Nessun dato | |
| Chief People Officer & Senior VP of IT | 5.8yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Commercial Officer | 5.4yrs | US$1.46m | 0% $ 0 | |
| Chief Business Officer | 1.1yrs | US$1.61m | 0.021% $ 169.5k | |
| Chief Regulatory Officer | 2.7yrs | Nessun dato | Nessun dato | |
| Senior VP and Head of Development & Program Management | 1.3yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | less than a year | Nessun dato | Nessun dato | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | Nessun dato |
1.8yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di EYPT non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 1.3yrs | US$2.92m | 0.091% $ 751.0k | |
| Interim Head of R&D and Director | 6.1yrs | US$161.67k | 0.017% $ 141.5k | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | Nessun dato | |
| Independent Non-Executive Chairman | 6.4yrs | US$214.78k | 0.020% $ 163.2k | |
| Independent Director | 5.3yrs | US$171.67k | 0.015% $ 123.7k | |
| Vice Chair | 8.2yrs | US$3.74m | 0.34% $ 2.8m | |
| Co- Chairman of Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato | |
| Member of Executive Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato | |
| Independent Director | 2.3yrs | US$149.17k | 0.025% $ 204.7k | |
| Co-Chair of Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato | |
| Member of Executive Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato | |
| Member of Executive Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato |
3.3yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EYPT sono considerati esperti (durata media dell'incarico 3.3 anni).